SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    ParkinDM, WhelanSL, FerlayJ, RaymondL, YoungJ, eds. Cancer incidence in five continents. vol. VII. IARC Sci Publ 143. Lyon: IARC, 1997.
  • 2
    Auvinen A, Rietbergen J, Gohagen J, Denis L, Schröder F. Prospective evaluation plan for randomised trials of prostate cancer screening. J Med Screen 1996; 3: 97104.
  • 3
    de Koning H, Auvinen A, Berenguer Sanchez A, Calais da Silva F, Ciatto F, Denis L, Gohagan J, Hakama M, Hugosson J, Kranse R, Nelen V, Prorok P, Schröder FH. The European Randomised Study of Screening for Prostate Cancer. Int J Cancer 2001; 97: 23744.
  • 4
    Hakama M. Screening. In: HollandWW, DetelsR, KnoxG, eds. Oxford textbook of public health. Applications in public health, 2nd ed. vol 3. Oxford: Oxford University Press, 1991. 96110.
  • 5
    IARC. Breast cancer screening. IARC handbook of cancer prevention. Lyon: IARC, 2002.
  • 6
    Määttänen L, Auvinen A, Stenman UH, Tammela T, Aro J, Juusela H, Hakama M. Three-year results of the Finnish Randomised Study of Prostate Cancer Screening. J Natl Cancer Inst 2001; 93: 5523.
  • 7
    Teppo L, Pukkala E, Lehtonen M. Data quality and quality control of a population-based cancer registry. Acta Oncol 1994; 33: 3659.
  • 8
    Labrie F, Dupont A, Suburu R, Cusan L, Tremblay M, Gomez JL, Emond J. Serum prostate specific antigen as pre-screening test for prostate cancer. J Urol 1992; 147: 84651.
  • 9
    Hoffman RM, Gilliland FD, Adams-Cameron M, Hunt WC, Key CR. Prostate-specific antigen testing accuracy in community practice. BMC Fam Pract 2002; 3: 19.
  • 10
    Mettlin C, Littrup PJ, Kane RA, Murphy GP, Lee F, Chesley A, Badalament R, Mostofi FK. Relative sensitivity and specificity of serum prostate specific antigen (PSA) level compared with age-referenced PSA, PSA density, and PSA change. Cancer 1994; 74: 161520.
  • 11
    Carter HB, Pearson JD, Metter EJ, Brant LJ, Chan DW, Andres R, Fozard JL, Walsh PC. Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease. JAMA 1992; 267: 221520.
  • 12
    Hakama M, Stenman UH, Aromaa A, Leinonen J, Hakulinen T, Knekt P. Validity of the prostate specific antigen test for prostate cancer screening: follow-up study with a bank of 21,000 sera in Finland. J Urol 2001; 166: 218991.
  • 13
    Gann PH, Hennekens CH, Stampfer MJ. A prospective evaluation of plasma prostate-specific antigen for detection of prostatic cancer. JAMA 1995; 273: 28994.
  • 14
    Parkes C, Wald NJ, Murphy P, George L, Watt HC, Kirby R, Knekt P, Helzlsouer KJ, Tuomilehto J. Prospective observational study to assess value of prostate specific antigen as screening test for prostate cancer. BMJ 1995; 311: 13403.
  • 15
    Draisma G, Boer R, Otto S, van der Cruisen IW, Damhuis RA, Schröder FH, de Koning HJ. Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomised Study of Screening for Prostate Cancer. J Natl Cancer Inst 2003, 95: 86878.